UBS Group AG reduced its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) by 14.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,223 shares of the company's stock after selling 24,463 shares during the quarter. UBS Group AG owned 0.84% of Global X Genomics & Biotechnology ETF worth $1,747,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Simplex Trading LLC lifted its position in Global X Genomics & Biotechnology ETF by 198.6% during the 3rd quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock worth $29,000 after buying an additional 1,537 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Global X Genomics & Biotechnology ETF by 26.2% during the 3rd quarter. Avantax Advisory Services Inc. now owns 26,650 shares of the company's stock worth $334,000 after buying an additional 5,539 shares in the last quarter. Portland Global Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 6.0% during the 3rd quarter. Portland Global Advisors LLC now owns 211,040 shares of the company's stock worth $2,649,000 after buying an additional 11,925 shares in the last quarter. Sightline Wealth Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 32.9% during the 3rd quarter. Sightline Wealth Advisors LLC now owns 54,420 shares of the company's stock worth $685,000 after buying an additional 13,458 shares in the last quarter. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth about $175,000. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ:GNOM opened at $12.58 on Thursday. The company's 50-day moving average price is $13.16 and its two-hundred day moving average price is $13.13. Global X Genomics & Biotechnology ETF has a one year low of $10.48 and a one year high of $16.75. The stock has a market capitalization of $211.09 million, a PE ratio of -5.38 and a beta of 1.02.

Global X Genomics & Biotechnology ETF Profile

(Get Rating)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

See Also

• Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
• META Platforms May See its Biggest Opening Yet for New Highs
• Penny Stock Vinco Ventures Could Be Big Winner
• Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
• Should You Park Some Capital with Casey's General Stores?
• Crowdstrike Stock: While The Iron Is Hot!

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.